P53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer Journal Article
| Authors: | Kudahetti, S.; Fisher, G.; Ambroisine, L.; Foster, C.; Reuter, V.; Eastham, J.; Møller, H.; Kattan, M. W.; Cooper, C. S.; Scardino, P.; Cuzick, J.; Berney, D. M. |
| Article Title: | P53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer |
| Abstract: | OBJECTIVE To determine whether p53 is an independent biomarker of prostate cancer outcome against currently used biomarkers in a cohort of conservatively treated prostate cancers with long-term follow-up available. PATIENTS AND METHODS We examined p53 expression by immunohistochemistry in a cohort of 705 patients with clinically localized prostate cancer, who were treated conservatively. Patients were selected through UK Cancer Registries. End-points included prostate cancer death and overall death rates. Standard biological variables, including diagnostic serum PSA, contemporary Gleason scoring, clinical staging and cancer extent were available. p53 expression was measured semi-quantitatively on microscopic examination and compared with current clinical biomarkers. RESULTS p53 over expression was a significant predictor of cause-specific survival (hazard ratio [HR] 2.95, 95% CI 2.05-4.25, P < 0.001) and overall survival (HR 2.37, 95% CI 1.84-3.05, P < 0.001). In multivariate analysis including competing biological variables p53 expression was still significantly linked to prostate cancer survival (HR 1.51, 95% CI 1.04-2.19, P = 0.03) and overall survival (HR 1.57, 95% CI 1.21-2.05, P = 0.001). CONCLUSIONS We conclude that p53 may have a role in the future assessment of newly diagnosed prostate cancer, as it significantly adds to the current prognostic model. © 2009 BJU International. |
| Keywords: | immunohistochemistry; adult; cancer survival; controlled study; protein expression; aged; middle aged; survival analysis; major clinical study; overall survival; microscopy; patient selection; disease marker; outcome assessment; follow up; prostate specific antigen; cohort studies; tumor markers, biological; cohort analysis; protein p53; cancer mortality; prostate cancer; gleason score; prostatic neoplasms; disease severity; biomarker; watchful waiting; tumor suppressor protein p53; cancer registry; predictor variable; multivariate analysis; protein determination; gleason; p53; cause specific survival |
| Journal Title: | BJU International |
| Volume: | 104 |
| Issue: | 1 |
| ISSN: | 1464-4096 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2009-07-01 |
| Start Page: | 20 |
| End Page: | 24 |
| Language: | English |
| DOI: | 10.1111/j.1464-410X.2009.08407.x |
| PUBMED: | 19239456 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 5" - "Export Date: 30 November 2010" - "CODEN: BJINF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work